Special Issue "Antibodies Therapies against Infectious Diseases"

Quicklinks

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (30 May 2014)

Special Issue Editor

Guest Editor
Dr. Gary R. McLean

Cellular and Molecular Immunology Research Centre, London Metropolitan University, London, UK
Website | E-Mail
Interests: recombinant antibodies; microvesicles/exosomes and viral infections; antibody therapeutics; vaccines

Special Issue Information

Dear Colleagues,

Approximately 30 monoclonal antibodies are currently licensed for use to treat human diseases such as cancer, autoimmune disorders, allergy and transplant rejection. However, just one monoclonal antibody (palivizumab) is licensed that targets an infectious disease pathogen (respiratory syncytial virus, RSV). Nevertheless, several antibodies (approximately 10 of 200) are undergoing preclinical development, or are in clinical trials, for viral infectious diseases. The current Special Issue welcomes contributions from experts in the field that address and review the current state-of-the art technology and developments in the field of antibody therapies against infectious diseases.

Dr. Gary McLean
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.


Keywords

  • monoclonal antibodies
  • infectious diseases
  • prophylactic
  • therapeutic
  • clinical trial

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Polyclonal Antibody Therapies for Clostridium difficile Infection
Antibodies 2014, 3(4), 272-288; doi:10.3390/antib3040272
Received: 26 August 2014 / Revised: 18 September 2014 / Accepted: 28 September 2014 / Published: 28 October 2014
Cited by 1 | PDF Full-text (2869 KB) | HTML Full-text | XML Full-text
Abstract
Clostridium difficile infection has emerged as a growing worldwide health problem. The colitis of Clostridium difficile infection results from the synergistic action of C. difficile secreted toxins A and B upon the colon mucosa. A human monoclonal IgG anti-toxin has demonstrated the ability
[...] Read more.
Clostridium difficile infection has emerged as a growing worldwide health problem. The colitis of Clostridium difficile infection results from the synergistic action of C. difficile secreted toxins A and B upon the colon mucosa. A human monoclonal IgG anti-toxin has demonstrated the ability in combination therapy to reduce mortality in C. difficile challenged hamsters. This antibody is currently in a clinical trial for the treatment of human Clostridium difficile infection. More than one group of investigators has considered using polyclonal bovine colostral antibodies to toxins A and B as an oral passive immunization. A significant proportion of the healthy human population possesses polyclonal antibodies to the Clostridium difficile toxins. We have demonstrated that polyclonal IgA derived from the pooled plasma of healthy donors possesses specificity to toxins A and B and can neutralize these toxins in a cell-based assay. This suggests that secretory IgA prepared from such pooled plasma IgA may be able to be used as an oral treatment for Clostridium difficile infection. Full article
(This article belongs to the Special Issue Antibodies Therapies against Infectious Diseases)

Journal Contact

MDPI AG
Antibodies Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
antibodies@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Antibodies
Back to Top